Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation

Scopus BioPharma Inc. (SCPS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/16/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/02/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/15/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/08/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/24/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/23/2022 8-K Investor presentation
Docs: "Molecular Therapy, 2018 Patents US 9,688,982 US 10,758,624:"
03/04/2022 8-K Quarterly results
02/25/2022 8-K Changes in Registrant's Certifying Accountant  Interactive Data
02/18/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
01/20/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT",
"AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT"
01/10/2022 8-K/A Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
12/27/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/26/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "SERIES A ADDITIONAL INVESTMENT OPTION SCOPUS BIOPHARMA, INC. AIO Shares: _______  Issue Date: November 23, 2021 THIS SERIES A ADDITIONAL INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on the five year anniversary of the Authorized Share Increase Date but not thereafter, to subscribe for and purchase from Scopus Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this AIO shall be equal to the Exercise Price, as defined in Section 2. Section 1 .      &#823...",
"SERIES B ADDITIONAL INVESTMENT OPTION SCOPUS BIOPHARMA, INC. AIO Shares: _______ Issue Date: November 23, 2021 THIS SERIES B ADDITIONAL INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date and on or prior to 5:00 p.m. on the five year anniversary of the Authorized Share Increase Date but not thereafter, to subscribe for and purchase from Scopus Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this AIO shall be equal to the Exercise Price, as defined in Section 2. Section 1 .     ...",
"PLACEMENT AGENT ADDITIONAL INVESTMENT OPTION SCOPUS BIOPHARMA, INC. AIO Shares: _______ Issue Date: November 23, 2021 THIS PLACEMENT AGENT ADDITIONAL INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date and on or prior to 5:00 p.m. on the five year anniversary of the Authorized Share Increase Date but not thereafter, to subscribe for and purchase from Scopus Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this AIO shall be equal to the Exercise Price, as defined in Section 2. This AIO is being issued pursuan...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 21, 2021 between Scopus Biopharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each ...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of November 21, 2021, between Scopus Biopharma, Inc., a Delaware corporation , and each of the several purchasers signatory hereto . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser . The Company and each Purchaser hereby agrees as follows: 1. Definitions . Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “ Advice ” shall have the meaning set forth in Section 6. “ Effectiveness Date ” means, with respect to the Reg...",
"WARRANT CONTRIBUTION AGREEMENT",
"Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market New York, New York, November 22, 2021 – Scopus BioPharma Inc. , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has entered into securities purchase agreements with certain institutional investors in connection with a private placement priced at-the-market under Nasdaq rules of 3,000,000 shares of common stock, series A additional investment options to purchase up to 1,500,000 shares of common stock, and series B additional investment options to purchase up to 1,500,000 shares of common stock at a purchase price of $3.25 per share and associated AIOs for gross proceeds of $9.75 million, before deduct..."
09/30/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "WITNESSETH:"
09/13/2021 8-K Quarterly results
07/09/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/01/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune"
03/18/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/20/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Investor Presentation (January 2021)",
"Press Release"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy